Sugi Predict

Sugi Predict / Compounds / SCHEMBL186535

SCHEMBL186535

SCHEMBL186535

OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCNCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 16/20 0.56
▸ OPRL1 P41146 9/20 0.56
▸ OPRD1 P41143 8/20 0.55
▸ OPRK1 P41145 8/20 0.55
▸ DRD2 P14416 8/20 0.54
▸ HTR1A P08908 7/20 0.50
▸ DRD4 P21917 7/20 0.50
▸ HTR2A P28223 7/20 0.50
▸ HTR2C P28335 7/20 0.50
▸ HTR7 P34969 7/20 0.50
▸ SLC6A2 P23975 6/20 0.50
▸ SLC6A4 P31645 6/20 0.50
▸ SLC6A3 Q01959 6/20 0.50
▸ HTR1D P28221 6/20 0.50
▸ HRH2 P25021 6/20 0.50
▸ DRD3 P35462 6/20 0.50
▸ HTR2B P41595 6/20 0.50
▸ DRD1 P21728 5/20 0.50
▸ DRD5 P21918 5/20 0.50
▸ HTR6 P50406 5/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546606 1.00 OPRM1 (0.56) OPRM1OPRL1OPRD1OPRK1DRD2
SCHEMBL9312075 0.91 SLC6A2 (0.54) OPRM1OPRL1OPRD1OPRK1DRD2
SCHEMBL8277109 0.88 DRD2 (0.51) OPRM1OPRL1OPRD1OPRK1DRD2
SCHEMBL5775884 0.88 DRD2 (0.54) OPRM1OPRL1OPRD1OPRK1DRD2
SCHEMBL2270692 0.83 SLC6A2 (0.51) OPRM1OPRL1OPRD1OPRK1DRD2
SCHEMBL2268801 0.83 DRD2 (0.51) OPRM1OPRL1OPRD1OPRK1DRD2
SCHEMBL9312205 0.83 OPRM1 (0.51) OPRM1OPRL1OPRD1OPRK1DRD2
Hydrochloric Acid SCHEMBL2270628 0.82 OPRM1 (0.50) OPRM1OPRL1OPRD1OPRK1DRD2
SCHEMBL2721577 0.82 OPRM1 (0.56) OPRM1OPRL1OPRD1OPRK1DRD2
SCHEMBL2275324 0.82 DRD2 (0.46) OPRM1OPRL1OPRD1OPRK1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111196781-B Improved method for preparing pentafluoride 湖南中南制药有限责任公司 2023-07-28 — — CN claimed
CN-113122050-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 — — CN claimed
WO-2023102022-A1 4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-06-08 — — WO disclosed
CN-113122050-B Quantum dot ink and preparation method of quantum dot film TCL科技集团股份有限公司 2022-11-04 — — CN disclosed
CN-113122050-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 — — CN disclosed
US-9663537-B2 Chemokine receptor antagonists and methods of use MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-05-30 — — US disclosed
US-9556187-B2 Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-01-31 — — US disclosed
EP-3112370-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS Nissan Chemical Industries, Ltd. (JP) 2017-01-04 — — EP disclosed
US-20160102102-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-04-14 — — US disclosed
US-20160031908-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF KYOWA HAKKO KOGYO CO., LTD. (JP) 2016-02-04 — — US disclosed
US-9216999-B2 Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2015-12-22 — — US disclosed
US-4324791-A DERIVATIVES OF 3,3-DIPHENYL-2-PYRROLIDINONES A. H. ROBINS COMPANY, INC. (US) 1982-04-13 — — US disclosed
US-4175129-A Antiemetic 1-(benzoxazolylalkyl)-piperidine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1979-11-20 — — US disclosed
US-4160836-A Antiemetic 1-(benzothiazolylalkyl)piperidine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1979-07-10 — — US disclosed
US-4126688-A ANTIEMETIC 1-(BENZOTRIAZOLYL-ALKYL)-PIPERIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1978-11-21 — — US disclosed
US-4126687-A ANTIEMETIC, 1-(BENZIMIDAZOLYL-ALKYL)-PIPERIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1978-11-21 — — US disclosed
US-4120969-A ANALGETIC, ANTIDIARRHEAL ACTIVITY A. H. ROBINS COMPANY, INCORPORATED (US) 1978-10-17 — — US disclosed
US-4110333-A ANTIEMETIC INTERMEDIATES JANSSEN PHARMACEUTICA N.V. (BE) 1978-08-29 — — US disclosed
US-4076821-A 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) 1978-02-28 — — US disclosed
US-4066772-A ANTIEMETICS JANSSEN PHARMACEUTICA N.V. (BE) 1978-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102102-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS JAK2, JAK1, JAK3 OPRM1 1941/4885OPRL1 2346/4885OPRD1 1439/4885
US-20160031908-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF ACKR3, CCR2, CXCR2 OPRM1 549/4885OPRL1 106/4885OPRD1 709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.